Thanatporn ThreetongAnuchit PoonyathalangPisit PreechawatPanitha JindahraTanyatuth PadungkiatsagulKavin VanikietiFaculty of Medicine, Ramathibodi Hospital, Mahidol UniversityBurapha University2020-08-252020-08-252020-01-01Clinical Ophthalmology. Vol.14, (2020), 2051-205611775483117754672-s2.0-85088278426https://repository.li.mahidol.ac.th/handle/20.500.14594/58275© 2020 Threetong et al. Purpose: To evaluate the initial treatment response to low doses of prednisolone, compared with moderate doses, in ocular myasthenia gravis (OMG). Patients and Methods: A retrospective chart review of patients with adult-onset (age ≥15 years old) OMG, who were treated with prednisolone, was conducted. Subjects were divided into two groups according to their prednisolone dosing regimen. The low-dose group was defined as those with an average 12-week cumulative dose of prednisolone <0.435 mg/ kg/day and the moderate-dose group averaged 0.435–1.000 mg/kg/day. The primary outcome of interest was the comparison of clinical response to prednisolone at 12 weeks between the low-dose and moderate-dose groups. The secondary outcome was the difference in adverse events between treatment groups. Results: Of 34 subjects, 16 subjects (47.1%) were male. The mean age at onset was 44.0 ±18.1 years. The most common presenting ocular feature was ptosis with ophthalmoplegia (22 subjects, 64.7%), followed by isolated ptosis (nine subjects, 26.5%) and isolated ophthalmoplegia (three subjects, 8.8%). Half of the subjects were treated with low-dose prednisolone and the other half were treated with moderate-dose prednisolone. There were no substantial differences in baseline characteristics between treatment groups. After 12 weeks of treatment, nine of 17 subjects (52.9%) and 13 of 17 subjects (76.5%) in the low-and moderate-dose groups, respectively, were regarded as responsive to the prednisolone treatment (P=0.28). Adverse events were exclusively observed in the moderate-dose group. Conclusion: Treatment of OMG with an average 12-week cumulative dose of prednisolone <0.435 mg/kg/day (low dose) shows a comparable responsive outcome to 0.435–1.000 mg/ kg/day of prednisolone (moderate dose). Treating OMG with low-dose prednisolone can minimize prednisolone-related adverse events. However, a prospective randomized controlled trial with a larger study population is warranted in order to gain more insight into the proper dosage of prednisolone for OMG.Mahidol UniversityMedicineArticleSCOPUS10.2147/OPTH.S261259